Living Between Scans: Uncertainty, Hope and Life After a Dementia Diagnosis
In this guest article, ADI Board Member and dementia advocate, Bill Yeates, shares his post diagnosis journey, discussing the hopes and challenges of life between scans.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
ADI Launches the Alzheimer’s Disease Atlas
Access the world's first of its kind platform highlighting how countries diagnose, treat and support people living with dementia.
The 78th World Health Assembly agrees to extend the Global Action Plan on the Public Health Response to Dementia
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Donanemab Receives Marketing Authorisation in Australia, Brazil, and Mexico
Marketing authorisation has been granted for donanemab (Kisunla) in Australia, following announcements from Brazil, and Mexico, for the treatment of Alzheimer's disease. The authorisations in Brazil and Mexico were granted in April 2025, with the announcement of the Australian approval on 21 May 2025.
European Commission approves first disease-modifying treatment for Alzheimer’s disease in the EU
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
European Commission appeals board unable to reach verdict on lecanemab
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
ADI driving action in the Americas: Developing dementia care policies in Argentina, Curaçao and Mexico
In March 2025, ADI was involved in a range of engagements across the Latin American region, from high level symposiums in Curaçao and Mexico, to providing strategic input on draft bills in Argentina and the international bloc of Latin American countries MERCOSUR.
ADI Member Associations in Asia Pacific host dynamic webinars to share dementia expertise
In March 2025, multiple member associations in the Asia Pacific region, including Australia, India, Japan, New Zealand, Philippines, Thailand and Taiwan conducted and participated in crucial online webinars to drive forward knowledge and expertise, helping to improve the lives of those living with dementia in the region.
ADASA hosts ADI visit: showcasing regional dementia services in South Africa
In March ADI Membership Manager, Gloria Mantineo, travelled to South Africa to visit the country member association ADASA, meeting with CEO, Marlene Freislich and regional leadership teams in South Africa’s three most populous provinces Gauteng, KwaZulu-Natal and Western Cape; to learn more about their services and gain greater insight into the work being undertaken within the country as well as the African region more broadly.
EMA’s CHMP recommends against granting marketing authorisation for donanemab
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended against granting the marketing authorisation of donanemab across the European Union’s Member States and European Economic Area (EEA). This is likely to be the second disease modifying therapy to be denied by the bloc, after the EMA declined aducanumab, leaving lecanemab as the only disease modifying therapy likely to achieve marketing authorisation.